A new gene therapy player debuts in LA with 2 startup VCs at its back, AbbVie on board with a $90M cash upfront and big plans to upend the field

These days, news of a biotech breaking out of stealth mode with a healthy launch round is not all that unusual. But Capsida just might surprise you in all sorts of ways.

Beth Seidenberg

Backed by 2 VCs that arrived at the same CalTech scientist’s...

Click to view original post